Physician profile
Alexander E Weingarten
NPI 1558353078
$42,520.16
in general payments reported to CMS, 2019-2025
65 companies · $4,812 in 2025
The $4,812 reported for 2025 was more than what 90% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,890 · 2021: $7,761 · 2022: $3,155 · 2023: $3,776 · 2024: $3,729 · 2025: $4,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $1,000 · Education: $15.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,302.73 |
| Honoraria | $1,000.00 |
| Education | $15.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $7,224.52 | 2019-2020 | |
| West Therapeutics Development, LLC | $5,056.31 | 2019 | |
| Collegium Pharmaceutical, INC. | $3,228.95 | 2019-2025 | Belbuca, Xtampza, Nucynta |
| Abbvie INC. | $2,596.95 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Scilex Pharmaceuticals INC. | $2,336.15 | 2019-2025 | Ztlido |
| Regeneron Pharmaceuticals, INC. | $1,860.00 | 2021 | |
| Biodelivery Sciences International, INC. | $1,798.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,458.76 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $1,425.42 | 2021 | |
| Protega Pharmaceutials INC | $1,359.57 | 2023-2025 | Roxybond |
| Tersera Therapeutics LLC | $993.53 | 2019-2025 | Prialt |
| Redhill Biopharma INC. | $961.92 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Forte Bio-Pharma LLC | $959.43 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Pfizer INC. | $928.53 | 2019-2025 | |
| Valinor Pharma, LLC | $886.91 | 2023-2025 | Movantik |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Weingarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.